[Therapy with cefotaxime-cefotaxime/ticarcillin for bronchopulmonary infections in patients under intensive care. (author's transl)].
55 intensive care patients with an internal underlying disease were treated with cefotaxime, and 12 patients with bronchopulmonary infections were treated with the combination cefotaxime/ticarcillin. The following aspects were evaluated: clinical success, antimicrobial activity of bacteria in evidence before and after therapy, persistence of pathogens, and resistance. Renal function was monitored continuously in 21 patients over a period of 20 days in order to demonstrate nephrotoxic side-effects of cefotaxime when administered simultaneously with furosemide (in doses of mre than 1 g/day). In view of the clinical results and of the fact that the cefotaxime/ticarcillin combination is well tolerated by the kidneys, the possibility of efficient chemotherapy without aminoglycosides is being discussed for treatment of bronchopulmonary infections in patients under intensive care.
D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy*; D002439:Cefotaxime / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003422:Critical Care; D004338:Drug Combinations; D005260:Female; D005665:Furosemide / Q000008:administration & dosage; D006801:Humans; D007668:Kidney / Q000187:drug effects; D008171:Lung Diseases / Q000188:drug therapy*; D008297:Male; D010406:Penicillins / Q000627:therapeutic use*; D013982:Ticarcillin / Q000008:administration & dosage / Q000627:therapeutic use*
D004338:Drug Combinations; D010406:Penicillins; D005665:Furosemide; D013982:Ticarcillin; D002439:Cefotaxime
Therapie bronchopulmonaler Infektionen bei Intensivpatienten mit Cefotaxim-Cefotaxim/Ticarcillin.